Setting traps for NKG2A gives NK cell immunotherapy a fighting chance

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E–expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.

Original languageEnglish (US)
Pages (from-to)1839-1841
Number of pages3
JournalJournal of Clinical Investigation
Volume129
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Natural Killer Cells
Immunotherapy
Adoptive Transfer
Endoplasmic Reticulum
Neoplasms
NK 2
Proteins

PubMed: MeSH publication types

  • Journal Article

Cite this

Setting traps for NKG2A gives NK cell immunotherapy a fighting chance. / Cichocki, Frank M; Miller, Jeffrey S.

In: Journal of Clinical Investigation, Vol. 129, No. 5, 01.05.2019, p. 1839-1841.

Research output: Contribution to journalReview article

@article{37e84cb16efa42dfaaace8d27adef8a6,
title = "Setting traps for NKG2A gives NK cell immunotherapy a fighting chance",
abstract = "The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E–expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.",
author = "Cichocki, {Frank M} and Miller, {Jeffrey S}",
year = "2019",
month = "5",
day = "1",
doi = "10.1172/JCI128480",
language = "English (US)",
volume = "129",
pages = "1839--1841",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Setting traps for NKG2A gives NK cell immunotherapy a fighting chance

AU - Cichocki, Frank M

AU - Miller, Jeffrey S

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E–expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.

AB - The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E–expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.

UR - http://www.scopus.com/inward/record.url?scp=85064852842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064852842&partnerID=8YFLogxK

U2 - 10.1172/JCI128480

DO - 10.1172/JCI128480

M3 - Review article

C2 - 30985296

AN - SCOPUS:85064852842

VL - 129

SP - 1839

EP - 1841

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -